Relevant links

Strategic Fund News


The Strategic Fund of the Pan American Health Organization (PAHO) is a regional technical cooperation mechanism for pooled procurement of essential medicines and strategic health supplies. Thus, the Fund is a central component of PAHO's strategy to move towards Universal Health.

The Strategic Fund strengthens strategic supply management systems, providing technical cooperation to plan demand, guarantee rational use and avoid stock-outs in the countries of the Americas.

The  products purchased through the Fund meet international standards in safety, efficacy and quality.

All Ministries of Health and Government Institutions of the Public Health Services Network of the countries that are members of PAHO can purchase medicines and supplies through the Strategic Fund. To do this, you only need to sign an agreement with the Organization.

As of June 2018, 33 countries in Latin America and the Caribbean have signed agreements with PAHO to use the mechanism (Argentina, Bahamas, Barbados, Belize, Bermuda, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Ecuador, El Salvador , Guatemala, Grenada, Guyana, Haiti, Honduras, Turks and Caicos Islands, British Virgin Islands, Jamaica, Nicaragua, Panama, Paraguay, Peru, Dominican Republic, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay and Venezuela).

In 2017, countries made over 437 purchase requests to the Strategic Fund for a total of more than US$90 million dollars.

The products include medicines to treat communicable diseases such as HIV, tuberculosis, malaria, Chagas, hepatitis and other neglected diseases; also, medicines for the treatment of non-communicable diseases; medical devices and equipment, and supplies such as insecticides, mosquito nets for the control of vectors, and diagnostics reagents.

The selection of these products is based on the list of medicines and essential diagnoses of the World Health Organization (WHO), products that are in the WHO Guidelines, as well as others considered strategic for the Region backed by scientific evidence that are considered high cost, limited availability or difficult to acquire in the national pharmaceutical markets.

View the  complete list of medicines and supplies that can be purchased through the Strategic Fund, along with reference prices and information on ordering procedures.

Here are some benefits to using the Strategic Fund:

-Economies of scale, competitive prices: consolidates the demand of multiple countries and calls for international bids to acquire quality assured supplies at lower prices.
Assured quality: products prequalified by WHO, registered in the National Regulatory Authorities of reference medicines of the Region or evaluated through internal processes for the assurance of quality.
Financial support: access to interest-free credit line, through the capitalization account of the Strategic Fund.
Access to products with limited availability: second-line treatments for tuberculosis, medicines for neglected diseases or pediatric antiretroviral and others with limited availability.

Steps for purchasing through the Strategic Fund:


Participate: Sign an agreement with the PAHO Strategic Fund


Plan: Prepare a procurement plan based on the estimate of your needs and the deadlines required by the Organization to complete the process.


Request: Submit an official purchase request for a specific number of units.


Approve: PAHO sends a quote from the provider that includes freight and insurance to the port of delivery that must be approved by the consignee.


Financing: The country must transfer the funds for the purchase to PAHO, according to the quotation, or request a line of credit from the capitalization account.


Reception of the products: The supplier delivers the products at the port of entry established by the country and the consignee performs the respective nationalization.

Countries that purchase products through the Strategic Fund must transfer the funds to PAHO in accordance with the estimate of the purchase. Otherwise, they can access the credit line.

The costs of acquiring products include the product price, freight and insurance, plus 4.25% of each purchase order directed to administration expenses (1.25%) and 3% for the solidarity capitalization account destined to finance the lines of credit.


The Strategic Fund is an innovative cooperation model that seeks to strengthen the management of the regional and national supply chain for essential medical products, so that everyone throughout the Region can enjoy the benefit of timely access to medicines and other strategic health supplies. The achievements of 2017 reflect the advances that have been made collectively by our Member States as they continue to expand access to medicines and other essential supplies, and move progressively towards the achievement of universal health.

The Annual Report 2017 -PAHO Strategic Fund. Access to high-quality medicines and health technologies in the Americas Annual Report 2017 -PAHO Strategic Fund. Access to high-quality medicines and health technologies in the Americas (PDF,)-summarizes the activities of the Fund during this period.

To find out more about the Strategic Fund, place an order, or get help in estimating demand for the products you need, contact the PAHO office in your country, or e-mail us at: This email address is being protected from spambots. You need JavaScript enabled to view it.

The Strategic Fund in Numbers


Member States have signed agreements to use the Strategic Fund.


products of assured quality available through the Strategic Fund.


growth in the use of the Strategic Fund since 2004 (in millions of US $)


Member States obtained interest-free credit lines through the capitalization account of the Strategic Fund for the acquisition of medicines and strategic public health supplies.

75 +

suppliers offering products through the Strategic Fund.



Annual Report. PAHO Strategic Fund. Access to high-quality medicines and health technologies in the Americas.

| 2017 | - | 2016 |

Recommendations of the Expert Committee for the Selection and Inclusion of Medicines in the PAHO Strategic Fund.

| 2016 | - | 2013 |

PAHO/WHO Strategic Fund - Brochure | Spanish - English |

Other information